Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-10 ل  8,802 نتائج ل ""Local""

فلترة النتائج

Subject : antineoplastic combined chemotherapy protocols Subject : breast cancer Subject : medicine.disease فلترة بواسطة : موضوع
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach.

  • Authors : Liu X; Pediatric Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No.107, Yanjiang West Road, Yuexiu District, Guangzhou, 510120, Guangdong, China.; Peng X

Subjects: Arsenic Trioxide*/Arsenic Trioxide*/Arsenic Trioxide*/administration & dosage ; Arsenic Trioxide*/Arsenic Trioxide*/Arsenic Trioxide*/therapeutic use ; Neuroblastoma*/Neuroblastoma*/Neuroblastoma*/drug therapy

  • Source: BMC cancer [BMC Cancer] 2024 Sep 12; Vol. 24 (1), pp. 1140. Date of Electronic Publication: 2024 Sep 12.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.

  • Authors : Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seoul, 03722, Republic of Korea. .; Severance Hospital and Yonsei University, 50-1 Yonsei-Ro, Seoul, Korea. .

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects

  • Source: BMC cancer [BMC Cancer] 2024 Jul 25; Vol. 23 (Suppl 1), pp. 1254. Date of Electronic Publication: 2024 Jul 25.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

[The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer].

  • Authors : Yang M; Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China.; Wang JJ

Subjects: Indazoles*/Indazoles*/Indazoles*/adverse effects ; Indazoles*/Indazoles*/Indazoles*/therapeutic use ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/drug therapy

  • Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Jul 23; Vol. 46 (7), pp. 696-702.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium: Print ISSN: 0253-3766

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

Subjects: Paclitaxel*/Paclitaxel*/Paclitaxel*/administration & dosage ; Paclitaxel*/Paclitaxel*/Paclitaxel*/therapeutic use ; Paclitaxel*/Paclitaxel*/Paclitaxel*/adverse effects

  • Source: BMC cancer [BMC Cancer] 2024 Jul 22; Vol. 24 (1), pp. 876. Date of Electronic Publication: 2024 Jul 22.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.

  • Authors : Lian D; School of Public Health, Fudan University, Shanghai, China.; National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China.

Subjects: Cost-Benefit Analysis* ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/economics

  • Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (10), pp. e7243.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study.

  • Authors : Chen GL; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.

Subjects: Aminopyridines*/Aminopyridines*/Aminopyridines*/adverse effects ; Aminopyridines*/Aminopyridines*/Aminopyridines*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

  • Source: Cancer medicine [Cancer Med] 2024 Aug; Vol. 13 (16), pp. e70142.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.

  • Authors : Eslami M; Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.; School of paramedical, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Subjects: Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/pathology ; Rituximab*/Rituximab*/Rituximab*/administration & dosage

  • Source: PloS one [PLoS One] 2024 Aug 01; Vol. 19 (8), pp. e0308247. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study.

  • Authors : Dogliotti I; Division of Hematology, University Hospital A.O.U. 'Città della Salute e della Scienza', Turin, Italy.; Peri V

Subjects: Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/mortality ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/pathology

  • Source: Cancer medicine [Cancer Med] 2024 Jul; Vol. 13 (14), pp. e7448.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.

  • Authors : Olawaiye AB; University of Pittsburgh School of Medicine and Magee-Womens Hospital, Gynecologic Oncology Group, Pittsburgh, PA, USA. .; Kim JW

Subjects: Albumins*/Albumins*/Albumins*/administration & dosage ; Albumins*/Albumins*/Albumins*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

  • Source: Journal of gynecologic oncology [J Gynecol Oncol] 2024 Jul; Vol. 35 (4), pp. e111.Publisher: Asian Society of Gynecologic Oncology Country of Publication: Korea (South) NLM ID: 101483150 Publication Model: Print Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Peripheral blood stem cells mobilization in patients with relapsed or refractory lymphomas: A single-center experience.

  • Authors : Halacoglu A; Department of Hematology, Medicalpark Gaziosmanpasa Hospital, Istinye University Faculty of Medicine, Istanbul, Turkey.; Serefhanoglu S

Subjects: Hematopoietic Stem Cell Mobilization*/Hematopoietic Stem Cell Mobilization*/Hematopoietic Stem Cell Mobilization*/methods ; Salvage Therapy*/Salvage Therapy*/Salvage Therapy*/methods ; Peripheral Blood Stem Cells*/Peripheral Blood Stem Cells*/Peripheral Blood Stem Cells*/metabolism

  • Source: Journal of cancer research and therapeutics [J Cancer Res Ther] 2024 Apr 01; Vol. 20 (3), pp. 904-908. Date of Electronic Publication: 2023 Dec 15.Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-10 ل  8,802 نتائج ل ""Local""